The weaknesses of science for profit.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

A new initiative on precision medicine. N Engl J Med (2015) 16.03

Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A (2014) 14.78

The knockout mouse project. Nat Genet (2004) 7.80

Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70

Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70

Statement on scientific publication and security. Science (2003) 3.04

Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development (2004) 2.84

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25

Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15

Statement on the consideration of biodefence and biosecurity. Nature (2003) 2.09

Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J (2012) 1.89

Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci U S A (2004) 1.89

Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev (2009) 1.76

Uncensored exchange of scientific results. Proc Natl Acad Sci U S A (2003) 1.73

Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med (2011) 1.54

Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol (2003) 1.54

Ten years on--the human genome and medicine. N Engl J Med (2010) 1.52

Casein kinase Iepsilon modulates the signaling specificities of dishevelled. Mol Cell Biol (2004) 1.41

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech (2009) 1.34

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27

A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol (2003) 1.26

Requirement for a nuclear function of beta-catenin in Wnt signaling. Mol Cell Biol (2003) 1.14

Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol (2007) 1.13

Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci U S A (2012) 1.05

Getting ready for gene-based medicine. N Engl J Med (2002) 1.00

The enlightenment returns. Science (2009) 0.97

Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. J Biomol Screen (2009) 0.93

Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis. Proc Natl Acad Sci U S A (2011) 0.88

Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS One (2009) 0.87

Support for the Human Cancer Genome Project. Science (2005) 0.86

Newsmaker interview: Harold Varmus. Piloting cancer research with a shrinking budget. Interview by Jocelyn Kaiser. Science (2011) 0.78

NIH funds support more than a researcher's own lab. Nature (2008) 0.75

Progress toward public access to science. PLoS Biol (2008) 0.75

NIH cancer chief wants more with less: by Meredith Wadman. Nature (2011) 0.75

Varmus Returns to His Roots in Cancer Genetics. JAMA (2015) 0.75

Harold Varmus. Interview by Errol C. Friedberg. Nat Rev Mol Cell Biol (2008) 0.75

A Prize for Cancer Prevention. Cell (2017) 0.75

Re-aim blame for NIH's hard times. Science (2006) 0.75

A conversation with Harold Varmus. Interview by Ushma S. Neill. J Clin Invest (2012) 0.75